No new SARS-CoV-2 variant of concern has been designated by WHO or ECDC in 2026, with both agencies reporting zero VOCs currently in circulation as of June and July updates. Circulating strains like BA.3.2 (nicknamed Cicada) and XFG sublineages show notable spike mutations and some immune-escape traits but have not triggered the required thresholds for increased severity, transmissibility, or vaccine impact to warrant VOC status. Ongoing genomic surveillance through wastewater, traveler testing, and clinical samples continues to track subvariants without evidence of rapid escalation. Updated 2026-2027 vaccines target dominant JN.1 lineages, and broad population immunity from prior exposures further dampens the odds of a concerning new emergence in the remaining months before 2027. Trader consensus at 88% for “No” reflects these stable conditions and the high bar for official designation.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
$243,960 Vol.
$243,960 Vol.
Oui
$243,960 Vol.
$243,960 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Marché ouvert : Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...No new SARS-CoV-2 variant of concern has been designated by WHO or ECDC in 2026, with both agencies reporting zero VOCs currently in circulation as of June and July updates. Circulating strains like BA.3.2 (nicknamed Cicada) and XFG sublineages show notable spike mutations and some immune-escape traits but have not triggered the required thresholds for increased severity, transmissibility, or vaccine impact to warrant VOC status. Ongoing genomic surveillance through wastewater, traveler testing, and clinical samples continues to track subvariants without evidence of rapid escalation. Updated 2026-2027 vaccines target dominant JN.1 lineages, and broad population immunity from prior exposures further dampens the odds of a concerning new emergence in the remaining months before 2027. Trader consensus at 88% for “No” reflects these stable conditions and the high bar for official designation.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes